255 related articles for article (PubMed ID: 7994025)
1. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
2. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
[TBL] [Abstract][Full Text] [Related]
5. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
[TBL] [Abstract][Full Text] [Related]
6. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
Itoh T; Tamura S; Takemoto Y; Kakishita E
Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha.
Hasford J; Baccarani M; Hehlmann R; Anseri H; Tura S; Zuffa E
Blood; 1996 Jun; 87(12):5384-91. PubMed ID: 8652857
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
9. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
Hehlmann R; Heimpel H; Griesshammer M; Kolb HJ; Heinze B; Hossfeld DK; Wickramanayake PD; Essers U; Thiele J; Georgii A
Leukemia; 1992; 6 Suppl 3():110S-114S. PubMed ID: 1602805
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
11. Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival.
Hehlmann R; Heimpel H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():161-7. PubMed ID: 8951787
[TBL] [Abstract][Full Text] [Related]
12. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
Silver RT; Woolf SH; Hehlmann R; Appelbaum FR; Anderson J; Bennett C; Goldman JM; Guilhot F; Kantarjian HM; Lichtin AE; Talpaz M; Tura S
Blood; 1999 Sep; 94(5):1517-36. PubMed ID: 10477676
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A
Br J Haematol; 1997 Apr; 97(1):76-85. PubMed ID: 9136944
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Hehlmann R; Kister P; Willer A; Simon M; Schenk M; Seifarth W; Papakonstantinou G; Saussele S; Kolb HJ; Ansari H
Leukemia; 1994 Apr; 8 Suppl 1():S127-32. PubMed ID: 8152279
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.
Ohnishi K; Ohno R; Tomonaga M; Kamada N; Onozawa K; Kuramoto A; Dohy H; Mizoguchi H; Miyawaki S; Tsubaki K
Blood; 1995 Aug; 86(3):906-16. PubMed ID: 7620184
[TBL] [Abstract][Full Text] [Related]
16. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
[TBL] [Abstract][Full Text] [Related]
17. Progress with interferon in CML--results of the MRC UK CML III study.
Shepherd PC; Richards SM; Allan NC
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S15-8. PubMed ID: 8769693
[TBL] [Abstract][Full Text] [Related]
18. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P
Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986
[TBL] [Abstract][Full Text] [Related]
19. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group.
Ohnishi K; Tomonaga M; Kamada N; Onozawa K; Kuramoto A; Dohy H; Mizoguchi H; Miyawaki S; Tsubaki K; Miura Y; Omine M; Kobayashi T; Naoe T; Ohshima T; Hirashima K; Ohtake S; Takahashi I; Morishima Y; Naito K; Asou N; Tanimoto M; Sakuma A; Ohno R
Leuk Res; 1998 Sep; 22(9):779-86. PubMed ID: 9716008
[TBL] [Abstract][Full Text] [Related]
20. [Chronic myeloid leukemia].
Hehlmann R
Ther Umsch; 1996 Feb; 53(2):82-7. PubMed ID: 8629268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]